AU Patent

AU2020267264A1 — Fenfluramine for use in the treatment of dravet syndrome

Assigned to UNIVERSITY HOSPITAL ANTWERP · Expires 2020-12-17 · 5y expired

What this patent protects

An effective dose of fenfluramine or its pharmaceutically acceptable salt for use in a method of adjunctive treatment of seizures in a patient, such as a patient previously diagnosed with Lennox Gastaut syndrome (LGS).

USPTO Abstract

An effective dose of fenfluramine or its pharmaceutically acceptable salt for use in a method of adjunctive treatment of seizures in a patient, such as a patient previously diagnosed with Lennox Gastaut syndrome (LGS).

Drugs covered by this patent

Patent Metadata

Patent number
AU2020267264A1
Jurisdiction
AU
Classification
—
Expires
2020-12-17
Drug substance claim
No
Drug product claim
No
Assignee
UNIVERSITY HOSPITAL ANTWERP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.